X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CAR-T therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: TeneoBio
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 23, 2020
Details:
Poseida will apply licensed UniDab binders, which possess significant advantages over traditional single chain variable antibody fragment (scFv) binders, to develop its next generation CAR-T therapies. Targets were not disclosed.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALKS 4230,Lucitanib
Therapeutic Area: Oncology Product Name: ALKS 4230
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Colvis Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
The study evaluated the antitumor efficacy and mechanism of action of mALKS 4230, a mouse ortholog of ALKS 4230, and lucitanib as monotherapies and in combination in a preclinical syngeneic mouse model of colon cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SH-105
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Seroba Life Sciences
Deal Size: $8.3 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 06, 2020
Details:
The funding will support the advancement of the product pipeline, along with expansion of technical and commercial operations in both Ireland and the US.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
